Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) – Leerink Swann issued their FY2022 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued on Tuesday. Leerink Swann analyst A. Fadia anticipates that the specialty pharmaceutical company will earn $21.94 per share for the year. Leerink Swann currently has a “Outperform” rating and a $180.00 target price on the stock.
JAZZ has been the topic of several other reports. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 25th. Cantor Fitzgerald restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Sunday, December 3rd. FBR & Co started coverage on Jazz Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $206.00 price objective on the stock. Morgan Stanley started coverage on Jazz Pharmaceuticals in a research note on Thursday, October 5th. They set an “equal weight” rating and a $155.00 price objective on the stock. Finally, Zacks Investment Research cut Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $181.68.
Jazz Pharmaceuticals (NASDAQ JAZZ) opened at $135.59 on Friday. Jazz Pharmaceuticals has a one year low of $112.52 and a one year high of $163.75. The stock has a market capitalization of $8,128.76, a price-to-earnings ratio of 17.01, a P/E/G ratio of 0.73 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10.
Several institutional investors and hedge funds have recently modified their holdings of JAZZ. Toronto Dominion Bank increased its holdings in shares of Jazz Pharmaceuticals by 12.4% during the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 81 shares during the period. Advisor Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 62.4% during the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after purchasing an additional 550 shares during the period. SG Americas Securities LLC increased its holdings in shares of Jazz Pharmaceuticals by 13.0% during the second quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock valued at $215,000 after purchasing an additional 159 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in Jazz Pharmaceuticals during the second quarter worth about $227,000. Finally, Intl Fcstone Inc. acquired a new position in Jazz Pharmaceuticals during the second quarter worth about $230,000. 90.73% of the stock is currently owned by institutional investors.
In other news, SVP Iain Mcgill sold 8,000 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the transaction, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $139.15, for a total value of $27,830.00. The disclosure for this sale can be found here. Insiders have sold 17,552 shares of company stock worth $2,399,643 over the last three months. Corporate insiders own 4.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Equities Focus and is the property of of Equities Focus. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.equitiesfocus.com/2018/01/07/research-analysts-set-expectations-for-jazz-pharmaceuticals-plc-s-fy2022-earnings-jazz.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.